文献速递肿瘤 PET/CT核素与放射性配体治疗

分次给予213Bi-FAPI-46放射性药物治疗的可行性、耐受性与初步临床反应:终末期进展性转移性肿瘤患者的先导经验

Feasibility, Tolerability, and Preliminary Clinical Response of Fractionated Radiopharmaceutical Therapy with 213Bi-FAPI-46: Pilot Experience in Patients with End-Stage, Progressive Metastatic Tumors.
PubMed 文献 · J Nucl Med · 2024-12-03

本研究在6例经多线治疗的进展性转移性实体瘤患者中,评估分次给予α发射体213Bi-FAPI-46放射性药物治疗的可行性、耐受性和反应。患者平均接受1,609 MBq的213Bi-FAPI-46,分53次单次给药,每例5-12次(平均8.8次),每例持续长达107小时。治疗耐受良好,无不良副作用;视觉评估显示1例部分缓解(16.7%)、1例疾病稳定(16.7%)、4例疾病进展(66.7%)。作者认为分次213Bi-FAPI-46是较177Lu或90Y标记化合物更匹配FAPI-46药代动力学的有前景方法,但需更大样本研究评估实际疗效和长期效应。

要点

  • 6例进展性转移性实体瘤患者接受分次213Bi-FAPI-46治疗,平均1,609 MBq,分53次单次给药,每例5-12次(平均8.8次),每例持续长达107小时。
  • 治疗耐受良好,无不良副作用。
  • 视觉评估:1例部分缓解(16.7%)、1例疾病稳定(16.7%)、4例疾病进展(66.7%)。

核心结论

  • 分次给予短半衰期α发射体213Bi-FAPI-46是较177Lu或90Y标记化合物更匹配FAPI-46药代动力学的有前景方法。
  • 在该先导项目中,分次213Bi-FAPI-46放射性药物治疗耐受良好,短期内使6例患者中2例达到疾病消退或稳定。
  • 需要更大患者队列的进一步研究来评估该FAPI放射性药物治疗方案的实际疗效和长期效应。

研究设计与样本

  • 先导经验研究,纳入6例进展性转移性实体瘤患者(3例结肠癌、1例肛管癌、1例乳腺癌、1例前列腺癌),年龄16-77岁,其中4例女性、2例男性。
  • 患者接受平均1,609 MBq的213Bi-FAPI-46,分53次单次给药,每例5-12次(平均8.8次),每例持续长达107小时。
  • 6例患者中4例接受帕博利珠单抗辅助治疗。
  • 治疗前后进行18F-FDG PET/CT(4例)和68Ga-FAPI-46 PET/CT(5例),视觉评估并计算总病灶糖酵解和总病灶FAPI。

主要发现

  • 213Bi-FAPI-46放射性药物治疗耐受良好,无不良副作用。
  • 视觉反应评估:1例部分缓解(16.7%)、1例疾病稳定(16.7%)、4例疾病进展(66.7%)。
  • 缓解患者的总病灶糖酵解不适用、总病灶FAPI降低24.3%;疾病稳定患者分别降低10.6%和5.9%;4例进展患者分别平均升高104.4%和321.3%。

局限性

  • 原文结论指出需要更大患者队列的进一步研究来评估该FAPI放射性药物治疗方案的实际疗效和长期效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Radiopharmaceutical therapies (RPTs) based on fibroblast activation protein (FAP) and FAP inhibitors (FAPIs) are a new option for progressive metastatic cancer in patients pretreated multiple times. To date, published in-human data refer to initial experiences with β-emitting 90Y- and 177Lu-based RPT. However, the short tumor retention time of FAPI ligands is considered a major limitation of FAPI RPT. Therefore, fractionated FAPI RPT with 213Bi, an α-emitter with a half-life of 46 min, appears to be a promising FAPI RPT regimen. Here, we report on our initial experiences with regard to the feasibility, tolerability, and response of fractionated 213Bi-FAPI-46 RPT. Methods: Six patients (4 women and 2 men) with progressive metastatic solid tumors (3 colon cancer, 1 anal cancer, 1 breast cancer, and 1 prostate cancer) aged 16-77 y were treated with a mean of 1,609 MBq of 213Bi-FAPI-46, fractionated into 53 single applications (range, 5-12 RPT applications per patient; mean, 8.8 applications) over a period of up to 107 h per patient. Of the 6 patients, 4 patients received adjuvant treatment with pembrolizumab. 18F-FDG (4 patients) and 68Ga-FAPI-46 (5 patients) PET/CT scans were performed before and after RPT. PET images were assessed visually and by calculating total lesion glycolysis and total lesion FAPI. Results: RPT with 213Bi-FAPI-46 was well tolerated without adverse side effects. In terms of visual response assessment, there was 1 partial response (16.7%), 1 patient with stable disease (16.7%), and 4 patients with progressive disease (66.7%). Concordantly, total lesion glycolysis and total lesion FAPI were decreased in the responding patient (not applicable and -24.3%, respectively), slightly decreased in the patient with stable disease (-10.6% and -5.9%, respectively), and increased in the 4 patients with progression (mean, +104.4% and +321.3%, respectively). Conclusion: Fractionated FAPI RPT with the short-half-life α-emitter 213Bi-FAPI-46 is a promising approach that matches the pharmacokinetics of FAPI-46 better than the 177Lu- or 90Y-labeled compounds. In this pilot project, fractionated RPT with 213Bi-FAPI-46 showed good clinical tolerability and even led to regressive or stable disease in the short term in 2 of 6 patients. Further studies with larger patient cohorts are required to evaluate the actual efficacy and long-term effects of this variant of FAPI RPT.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Helisch A, Kratochwil C, Kleist C, et al. Feasibility, Tolerability, and Preliminary Clinical Response of Fractionated Radiopharmaceutical Therapy with 213Bi-FAPI-46: Pilot Experience in Patients with End-Stage, Progressive Metastatic Tumors. J Nucl Med. 2024. PMID: 39477492. doi:10.2967/jnumed.124.268386

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。